Six-year follow-up of glutaraldehyde-preserved heterografts. With particular reference to the treatment of congenital valve malformations.
D000293:Adolescent; D000328:Adult; D000447:Aldehydes; D001021:Aortic Valve / Q000473:pathology / Q000601:surgery; D002648:Child; D004437:Ebstein Anomaly / Q000401:mortality / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D005976:Glutaral; D006349:Heart Valve Diseases / Q000151:congenital / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006350:Heart Valve Prosthesis; D006351:Heart Valves / Q000637:transplantation*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000002:abnormalities / Q000473:pathology / Q000601:surgery; D011183:Postoperative Complications; D011664:Pulmonary Valve / Q000002:abnormalities; D014021:Tissue Preservation; D014183:Transplantation, Heterologous; D014261:Tricuspid Valve / Q000473:pathology / Q000601:surgery
D000447:Aldehydes; D005976:Glutaral